Skip to main content

General Rheumatology

      Mimics of ANCA-associated vasculitis: How can we tell?

      With increased disease awareness and more regular, accessible te

      Dr. John Cush RheumNow

      1 week ago
      Mimics of ANCA-associated vasculitis: How can we tell? With increased disease awareness and more regular, accessible testing for anti-neutrophil cytoplasmic antibodies (ANCA), ANCA-associated vasculitis (AAV) has become an increasingly recognized clinical entity in rheumatologic https://t.co/LYRk0rHlzx
      “I never thought I’d live to old age with MCTD, now I plan for it.”

      This patient’s journey highlights the powe

      Jiha Lee JihaRheum

      1 week ago
      “I never thought I’d live to old age with MCTD, now I plan for it.” This patient’s journey highlights the power of evolving therapies, resilience, and lifestyle adaptation to age well with chronic autoimmune disease. Patient perspectives abstract #PP04 @rheumnow #ACR25
      #ClinicalPearl

      Pts w #SpA ex #PsA May have
      👇
      #sicca #dry #eyes #dry mouth

      Inflamed gallbladder without calculi
      👇

      Janet Pope Janetbirdope

      1 week ago
      #ClinicalPearl Pts w #SpA ex #PsA May have 👇 #sicca #dry #eyes #dry mouth Inflamed gallbladder without calculi 👇 Can be associated w #autoimmune disease #POTS can be initial presentation of #SjD IgA vasculitis—May have #cancer #Secrets & #Pearls #ACR25 @RheumNow @ACRheum https://t.co/4SAqVYjnrD
      Passive transfer of Ab can occur w #IVIg

      #Ab can occur from IVIg passive transfer incl HepB

      IVIg - if pt has #cryoglo

      Janet Pope Janetbirdope

      1 week ago
      Passive transfer of Ab can occur w #IVIg #Ab can occur from IVIg passive transfer incl HepB IVIg - if pt has #cryoglobulins 👇 Can precipitate severe #cryo flare #ClinicalPearl Secrets & Pearls session #ACR25 @RheumNow @ACRheum https://t.co/tTaSuVy1yQ
      #1726 IA from immune checkpoint inhibitors (ICI) is a distinct autoimmune entity: T cell-driven but not antibody-mediate

      Mrinalini Dey DrMiniDey

      1 week ago
      #1726 IA from immune checkpoint inhibitors (ICI) is a distinct autoimmune entity: T cell-driven but not antibody-mediated irAE arthritis shows hyperactive, cytotoxic CD8+ T cells & metabolic reprogramming, unlike RA. IL-6, IL-12 & IFNα fuel this process. @RheumNow #ACR25
      #ClinicalPearl

      #seroneg #arthritis often has
      👇
      #involvement of
      1st toe IP joint

      Look at the feet 🦶

      @RheumNow

      Janet Pope Janetbirdope

      1 week ago
      #ClinicalPearl #seroneg #arthritis often has 👇 #involvement of 1st toe IP joint Look at the feet 🦶 @RheumNow @ACRheum #ACR25 #28T08 Session secrets &pearls Tues https://t.co/EfqkLsTKmt
      Overview of the use of SARD-ILD by @drdavidliew covering the challenges, professionalism, explainability and interpretab

      Antoni Chan MD (Prof) synovialjoints

      1 week ago
      Overview of the use of SARD-ILD by @drdavidliew covering the challenges, professionalism, explainability and interpretability. Think of using and validating AI in the same way we train our residents. The human interface still needed @RheumNow #ACR25 https://t.co/TYKud057ag
      The Power of Gamma Delta T Cell for Autoimmunity https://t.co/wIMu5r7b3D

      More on T Cell engagers , this time with ga

      Nouf Al hemmadi NoufAhmedAlham2

      1 week ago
      The Power of Gamma Delta T Cell for Autoimmunity https://t.co/wIMu5r7b3D More on T Cell engagers , this time with gama delta T cell ( tiny but mighty ). Kate Roslin talks about advantages of this protocol. (No cytokines thus less toxicity). @Yuz6Yusof @RheumNow #ACR25
      #ACR25 Please find my video interview with Dr Kate Rochlin on a novel Bi-specific T-cell engager (BiTE) in development w

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 week ago
      #ACR25 Please find my video interview with Dr Kate Rochlin on a novel Bi-specific T-cell engager (BiTE) in development which binds to pan-gamma delta T-cell instead of CD3 to minimise risk of cytokine release syndrome side effect. Abstr#1535 @RheumNow https://t.co/MOmUm41cyA https://t.co/TgIUGgWGw5
      Two new studies presented this year tackle a key question: can our initial treatment choices influence who ends up in the difficult-to-treat category?
      🎥 LIVE from #ACR25
      Join us daily at 5 PM CST for RheumNow’s ACR Recap Live -
      Your must-watch debrief of the day’

      Dr. John Cush RheumNow

      1 week ago
      🎥 LIVE from #ACR25 Join us daily at 5 PM CST for RheumNow’s ACR Recap Live - Your must-watch debrief of the day’s biggest breakthroughs, hot abstracts, and real-time clinical takeaways. Streaming on YouTube Live, Facebook Live, X-Live & LinkedIn Live. Save the time. Be part of https://t.co/ZgZM14L6ta
      ×